NEW YORK (GenomeWeb News) – NextBio today announced a deal with the Winship Cancer Institute of Emory University to identify biomarkers and treatments for multiple myeloma.

The organizations will collaborate on a translational study using NextBio Clinical to interpret molecular data from patients with the disease, which constitutes only about 1 percent of all cancers in the US but has been especially difficult to treat. The goal of the study will be to make new discoveries that can improve care given to patients with refractory and relapsed forms of myeloma, NextBio said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."